Monday, February 22, 2016

Comparison: Osteoporosis Medications

 
  • All numbers needed to treat (NNT) are in comparison to placebo. These medications haven’t been directly compared
Based on Study
  • study was to perform a head-to-head comparison of efficacy and safety profile between 60 mg denosumab (Den) subcutaneously (SC) per 6 months (Q6M) and 70 mg alendronate (Aln) orally per week (QW) for postmenopausal women with low bone mineral density
  • The overall rates of AEs and SAEs were balanced between both groups
  • 60 mg Den SC Q6M therapy might be more effective for increasing the bone mass of postmenopausal women than the 70 mg Aln oral QW therapy. 
  • However the analysis of the relevant clinical outcome demonstrated inconclusive benefits of denosumab over alendronate, its safety profile was not fully clarified either. 
  • At present because of its relatively high price, denosumab could not completely replace alendronate for postmenopausal women.
Other Considerations:
  • Ensure all patients get adequate calcium and vitamin D
  • Consider estrogen therapy for prematurely menopausal women less than 50 years old for osteoporosis prevention.Otherwise, estrogen therapy is not indicated solely for prevention of osteoporosis.
  • Treating 10,000 women 50 to 79 years of age with estrogen/progestin for one year prevents six spine and six hip fractures. However, there will be eight more cases of breast cancer, nine more strokes, and 21 more thromboembolic events.
  • For patients with low fracture risk, adequate calcium and vitamin D, and estrogen if appropriate, may be all that is needed for osteoporosis prevention.
References:
  1. PL Detail-Document, Comparison of Medications for Osteoporosis. Pharmacist’s Letter/Prescriber’s Letter. July 2012.
  2. http://www.uspharmacist.com/content/c/30060/
  3. http://www.medscape.com/viewarticle/760954_4

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.